Paper Details

  1. Home
  2. Paper Details

Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.

Author: KojimaMasazumi, KunitadaSatoshi, MasumotoHiroshi, Mendell-HararyJeanne, OgataKoichiro, OgumaToshihiro, TachibanaMasaya

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Single and multiple doses of edoxaban, an oral direct factor Xa inhibitor, were safe and well tolerated in healthy males up to 150 mg.
Paper Details　
Original Abstract of the Article :
This is a clinical safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) study of a single ascending dose (SAD) and a multiple ascending dose (MAD) of the oral direct factor Xa inhibitor edoxaban in healthy males. The placebo-controlled, single-blind, randomized, 2-part study consis...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/0091270009351883

データ提供：米国国立医学図書館（NLM）

Edoxaban: A New Hope in the Desert of Blood Clot Prevention

Blood clots, a serious health concern that can lead to stroke, heart attack, and pulmonary embolism, require effective prevention strategies. This research explores the safety, tolerability, pharmacokinetics, and pharmacodynamics of edoxaban, a novel oral direct factor Xa inhibitor, in healthy volunteers. The study aimed to assess the safety and effectiveness of edoxaban in inhibiting blood clotting, providing valuable information for its potential use in preventing and treating thromboembolic events.

Edoxaban: A Promising Oasis in the Desert of Blood Clot Prevention

The study involved a two-part, single-blind, randomized, placebo-controlled trial in healthy male volunteers. The researchers found that edoxaban was safe and well-tolerated at doses up to 150 mg. Edoxaban demonstrated predictable pharmacokinetic and pharmacodynamic profiles, with a linear relationship between plasma concentrations and coagulation parameters. These findings suggest that edoxaban holds promise as a safe and effective agent for preventing and treating blood clots.

Edoxaban: A Potential Solution in the Desert of Thromboembolic Disease

This research provides crucial insights into the safety and efficacy of edoxaban, a promising new drug for preventing and treating blood clots. The study's findings support the further development and investigation of edoxaban as a potential treatment option for individuals at risk of thromboembolic events.

Dr.Camel's Conclusion

This research takes us on a journey through the desert of blood clot prevention, highlighting the potential of edoxaban as a safe and effective agent. Like a cool spring in the desert, edoxaban may provide a much-needed solution for individuals at risk of developing life-threatening blood clots. The study's findings offer hope for those seeking effective and reliable strategies to prevent and treat thromboembolic disease.

Date :
  1. Date Completed 2010-09-17
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

20081065

DOI: Digital Object Identifier

10.1177/0091270009351883

Related Literature

Article Analysis
・Effects of edoxaban
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.